Bone marrow transplantation (BMT) is an established treatment of many malignant and non-malignant hematologic diseases like acute leukemias, chronic leukemias, lymphomas, B-thalassemia major, severe aplastic anemia and congenital immunodeficiency syndromes. Autologous BMT requires the extraction (apheresis) of haematopoietic stem cells (HSC) from the patient and storage of the harvested cells in a freezer. The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient’s malignant cell population. The patient’s own stored stem cells are then transfused into his bloodstream, where they replace destroyed tissue and resume the patient’s normal blood cell production. Allogeneic BMT involves two people: the (healthy) donor and the (patient) recipient. Allogeneic HSC donors must have an HLA type that matches the recipient. Allogeneic transplant donors may be related (usually a closely HLA matched sibling), or unrelated (donor who is not related and found to have very close degree of HLA matching). All BMT rooms should meet the requirements for air filtration (by HEPA air-filtration system) and air circulation that help prevent infection and disease in immunocompromised patients. Conventional protective procedures include isolation in single patient room and combination of hand-washing, gloves, mask and gown.